0
Abstract: Poster Presentations |

NORMALIZATION OF SPIROMETRY IN SUBJECTS WITH EMPHYSEMA AND INTERSTITIAL LUNG DISEASE FREE TO VIEW

Karen Heathcote, MD*; Donald Cockcroft, MD; Derek Fladeland, MD; Mark Fenton, MD
Author and Funding Information

University of Saskatchewan, Saskatoon, SK, Canada


Chest


Chest. 2009;136(4_MeetingAbstracts):121S. doi:10.1378/chest.136.4_MeetingAbstracts.121S-a
Text Size: A A A
Published online

Abstract

PURPOSE:  Emphysema and interstitial lung disease produce opposing effects on expiratory flow rates and lung volumes on pulmonary function testing. However, both can cause reductions in the diffusing capacity for carbon monoxide (DLCO). Patients with concurrent emphysema and interstitial lung disease can present with normal expiratory flow rates and lung volumes, and a marked reduction in DLCO. In this study, we present a prospective series of ten such patients with interstitial lung disease and emphysema.

METHODS:  Symptomatic patients that presented with an isolated reduction in DLCO were identified prospectively from the respiratory outpatient clinic. The medical records, pulmonary function tests (PFT's) and laboratory tests at diagnosis and during follow up were reviewed. Chest radiograph and chest computed tomography (CT) scans were reviewed by a radiologist.

RESULTS:  The patients ranged in age from 50 to 85. PFT's revealed: vital capacity (VC) [94.9 ± 6.5]% of predicted, ratio of forced expiratory flow in one second to forced vital capacity (FEV1/FVC) [0.74 ± 0.04], total lung capacity (TLC) [96.0 ± 6.1]% of predicted, and DLCO [42.4 ± 8.6]% of predicted. Emphysema and interstitial lung disease were confirmed on chest radiographs and CT scans.

CONCLUSION:  Emphysema and interstitial processes occurring simultaneously in the lung can present with normal expiratory flow rates and lung volumes and isolated diffusion abnormalities.

CLINICAL IMPLICATIONS:  The differential diagnosis of an isolated reduction in diffusing capacity should include co-existing emphysema and interstitial lung disease.

DISCLOSURE:  Karen Heathcote, No Financial Disclosure Information; No Product/Research Disclosure Information

Wednesday, November 4, 2009

12:45 PM - 2:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
Guidelines
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543